The Subarachnoid Hemorrhage drugs in development market research report provides comprehensive information on the therapeutics under development for Subarachnoid Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Subarachnoid Hemorrhage. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Subarachnoid Hemorrhage and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Subarachnoid Hemorrhage by 19 companies/universities/institutes. The top development phase for Subarachnoid Hemorrhage is preclinical with eight drugs in that stage. The Subarachnoid Hemorrhage pipeline has 20 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Subarachnoid Hemorrhage pipeline products market are: Resolve Therapeutics, Acasti Pharma and Takeda Pharmaceutical.
The key targets in the Subarachnoid Hemorrhage pipeline products market include Disks Large Homolog 4, Voltage Dependent L Type Calcium Channel, and Voltage Dependent L Type Calcium Channel Subunit Alpha 1C.
The key mechanisms of action in the Subarachnoid Hemorrhage pipeline product include Voltage Dependent L Type Calcium Channel Blocker with two drugs in Phase II. The Subarachnoid Hemorrhage pipeline products include four routes of administration with the top ROA being Intravenous and seven key molecule types in the Subarachnoid Hemorrhage pipeline products market including Small Molecule, and Fusion Protein.
Subarachnoid Hemorrhage overview
Subarachnoid hemorrhage refers to the occurrence of bleeding within the subarachnoid space, the region between the brain and its delicate covering tissues. This condition demands immediate medical intervention due to its emergent nature. Causes encompass diverse factors, including arteriovenous malformations (AVMs), bleeding disorders, cerebral aneurysms, head injuries, and the use of blood thinners. The hallmark symptom is a sudden and severe headache, often described as a “thunderclap headache,” with notable intensity at the back of the head. Treatment objectives focus on preserving life, addressing the underlying cause, alleviating symptoms, and preventing complications like permanent brain damage. Surgical interventions may be necessary to evacuate blood collections, relieve pressure, or repair ruptured aneurysms associated with the hemorrhage.
For a complete picture of Subarachnoid Hemorrhage’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
